Dicerna Pharma (DRNA) Misses Q3 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Dicerna Pharma (DRNA) Misses Q3 EPS by 17c

Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress

November 7, 2019 4:05 PM EST

Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX2 Pivotal Clinical Trial

Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S.

$312.7 Million in Cash, Cash Equivalents, and Marketable Securities at September 30, 2019; Dicerna to Receive $200.0 Million Upon Close of HBV Agreement with Roche

Management to Host Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS... More